Wolf Popper LLP Investigates the Proposed Acquisition of Impax Laboratories, Inc. by Amneal Pharmaceuticals LLC
NEW YORK, October 24, 2017
Wolf Popper LLP is investigating claims on behalf of investors in Impax Laboratories, Inc. (NASDAQ: IPXL), concerning the all-stock proposed acquisition of Impax by Amneal Pharmaceuticals LLC, a private company. Under the terms of the proposed acquisition, Amneal members will own approximately 75% of the voting power of a new, publicly traded holding company, Amneal Pharmaceuticals, Inc. (“Amneal”) and Impax’s shareholders will own approximately 25% of the voting power of Amneal. However, there is no indication as to how that ratio was determined or the implied value per Impax share. According to Carl Stine, a partner at Wolf Popper LLP, “Without a definitive offer price, Impax’s public shareholders are left in the dark as to the true value of this deal. Looks to me like they’re trying to sell Impax’s shareholders a pig in a poke.”
Wolf Popper is investigating claims on behalf of investors in Impax concerning the transaction. Impax’s shareholders seeking more information about the transaction or Wolf Popper’s investigation can contact Mr. Stine at (212) 759-4600 or firstname.lastname@example.org.
Wolf Popper has extensive experience representing investors in mergers and acquisition lawsuits and has successfully ensured that investors receive the maximum compensation. Twelve Wolf Popper attorneys were named Super Lawyers or Rising Stars in the 2017 Super Lawyers New York City Metro Edition, including Wolf Popper partner Carl Stine, who was included in the Super Lawyers Top 100 List for the New York City Metro area. View Wolf Popper attorney biographies at www.wolfpopper.com.
Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.
Wolf Popper LLP
845 Third Avenue
New York, New York 10022
Toll Free Tel: 877-370-7703
Toll Free Fax: 877-370-7704